BILLIONTOONE INC CL A (BLLN) Stock Price & Overview

NASDAQ:BLLN • US0901681058

Current stock price

69.55 USD
-1.89 (-2.65%)
Last:

The current stock price of BLLN is 69.55 USD. Today BLLN is down by -2.65%. In the past month the price decreased by -8.88%.

BLLN Key Statistics

1-Month Range61.96 - 86.01
Current BLLN stock price positioned within its 1-month range.
Market Cap
3.197B
P/E
496.79
Fwd P/E
242.11
EPS (TTM)
0.14
Dividend Yield
N/A

BLLN Stock Performance

Today
-2.65%
1 Week
-8.49%
1 Month
-8.88%
3 Months
-22.12%
Longer-term
6 Months N/A
1 Year N/A
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A

BLLN Stock Chart

BILLIONTOONE INC CL A / BLLN Daily stock chart

BLLN Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to BLLN.


Chartmill TA Rating
Chartmill Setup Rating

BLLN Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to BLLN. BLLN has a great financial health rating, but its profitability evaluates not so good.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

BLLN Earnings

On March 4, 2026 BLLN reported an EPS of 0.11 and a revenue of 96.05M. The company beat EPS expectations (27.08% surprise) and beat revenue expectations (8.04% surprise).

Next Earnings DateN/A
Last Earnings DateMar 4, 2026
PeriodQ4 / 2025
EPS Reported$0.11
Revenue Reported96.053M
EPS Surprise 27.08%
Revenue Surprise 8.04%

BLLN Forecast & Estimates

14 analysts have analysed BLLN and the average price target is 125.29 USD. This implies a price increase of 80.14% is expected in the next year compared to the current price of 69.55.

For the next year, analysts expect an EPS growth of 76.15% and a revenue growth 47.34% for BLLN


Analysts
Analysts84.29
Price Target125.29 (80.14%)
EPS Next Y76.15%
Revenue Next Year47.34%

BLLN Groups

Sector & Classification

Index Membership

BLLN Financial Highlights

Over the last trailing twelve months BLLN reported a non-GAAP Earnings per Share(EPS) of 0.14. The EPS increased by 114.79% compared to the year before.


Income Statements
Revenue(TTM)305.11M
Net Income(TTM)2.92M
Industry RankSector Rank
PM (TTM) 0.96%
ROA 0.46%
ROE 0.61%
Debt/Equity 0.12
Chartmill High Growth Momentum
EPS Q2Q%103.94%
Sales Q2Q%-37.05%
EPS 1Y (TTM)114.79%
Revenue 1Y (TTM)99.97%

BLLN Ownership

Ownership
Inst Owners27.93%
Shares45.97M
Float20.27M
Ins Owners19.2%
Short Float %5.82%
Short Ratio4.2

About BLLN

Company Profile

BillionToOne, Inc. is a next-generation molecular diagnostics company on a mission to create powerful and accurate tests that are accessible to all. The company is headquartered in Menlo Park, California and currently employs 713 full-time employees. The company went IPO on 2025-11-06. The firm's proprietary molecular counting platform is designed to detect and measure deoxyribonucleic acid (DNA) molecules at a single-count level to help improve disease detection. The company applies the proprietary technology to non-invasive prenatal screening (Prenatal) and liquid biopsy (Oncology). Its Quantitative Counting Templates (QCTs), power its ability to detect and measure tiny and sparse disease-related DNA fragments, or molecules, at the single base-pair level. These include pregnancy-related DNA that code for recessively inherited conditions such as sickle cell disease and cystic fibrosis and ctDNA in the case of cancer. Its prenatal products include UNITY Complete, UNITY Fetal Risk Screen, UNITY Aneuploidy Screen, UNITY Fetal RhD NIPT, UNITY Fetal Antigen NIPT, and UNITY Fetal Antigen CTA NIPT. Its oncology products include Northstar and Northstar Select.

Company Info

IPO: 2025-11-06

BILLIONTOONE INC CL A

1035 O'brien Drive

Menlo Park CALIFORNIA US

Employees: 713

BLLN Company Website

Phone: 13025310855

BILLIONTOONE INC CL A / BLLN FAQ

What does BILLIONTOONE INC CL A do?

BillionToOne, Inc. is a next-generation molecular diagnostics company on a mission to create powerful and accurate tests that are accessible to all. The company is headquartered in Menlo Park, California and currently employs 713 full-time employees. The company went IPO on 2025-11-06. The firm's proprietary molecular counting platform is designed to detect and measure deoxyribonucleic acid (DNA) molecules at a single-count level to help improve disease detection. The company applies the proprietary technology to non-invasive prenatal screening (Prenatal) and liquid biopsy (Oncology). Its Quantitative Counting Templates (QCTs), power its ability to detect and measure tiny and sparse disease-related DNA fragments, or molecules, at the single base-pair level. These include pregnancy-related DNA that code for recessively inherited conditions such as sickle cell disease and cystic fibrosis and ctDNA in the case of cancer. Its prenatal products include UNITY Complete, UNITY Fetal Risk Screen, UNITY Aneuploidy Screen, UNITY Fetal RhD NIPT, UNITY Fetal Antigen NIPT, and UNITY Fetal Antigen CTA NIPT. Its oncology products include Northstar and Northstar Select.


What is the current price of BLLN stock?

The current stock price of BLLN is 69.55 USD. The price decreased by -2.65% in the last trading session.


Does BILLIONTOONE INC CL A pay dividends?

BLLN does not pay a dividend.


What is the ChartMill rating of BILLIONTOONE INC CL A stock?

BLLN has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 4 out of 10.


What is the ownership structure of BILLIONTOONE INC CL A (BLLN)?

You can find the ownership structure of BILLIONTOONE INC CL A (BLLN) on the Ownership tab.


What is the Short Interest ratio of BILLIONTOONE INC CL A (BLLN) stock?

The outstanding short interest for BILLIONTOONE INC CL A (BLLN) is 5.82% of its float.